Updated: July 2026
Published by Physician Growth Partners
Women’s health has become a strategically sought-after sector in physician practice M&A. The combination of a proven multi-platform consolidation history, a widening national OB/GYN access crisis, and an expanding clinical scope that now reaches across a woman’s entire lifespan, from reproductive health and obstetrics through menopause management, breast health, urogynecology, and fertility, has made independent women’s health practices among the most attractive assets available to private equity sponsors and strategic buyers today.
Private equity investment and consolidation in women’s health and OB/GYN practices began in 2013 with the formation of Unified Women’s Healthcare. Since then, the sector has gained significant momentum and evolved into a well-established consolidation theme, with multiple platforms completing second recapitalizations, new entrants actively building scale, and a growing group of strategic acquirers competing for high-quality practices across the full women’s health spectrum, including fertility MSOs, multi-specialty physician organizations, and health systems focused on addressing gaps in maternity care access. Independent OB/GYN and women’s health group owners who have built strong clinical reputations, loyal patient panels, and multi-specialty service capabilities are in a position of genuine leverage.
The U.S. women’s health market encompasses one of the broadest clinical continuums in all of healthcare; spanning obstetrics, gynecology, maternal-fetal medicine (MFM), fertility and reproductive endocrinology (REI), urogynecology, breast health, menopause management, behavioral health, and preventive wellness. The U.S. women’s health market is projected to reach $92.4 billion by 2031, driven by growing demand for comprehensive lifecycle care, rising menopause management adoption following the FDA’s February 2026 removal of outdated hormone therapy warnings, and accelerating digital health integration in fertility and reproductive care.[1] The U.S. OB/GYN and fertility care market specifically is valued at approximately $13.4 billion in 2025, while the adjacent femtech sector (digital fertility, telehealth-enabled menopause care, and remote monitoring) is projected to grow from to $37.4 billion by 2034.[2]
The investment thesis for women’s health is further strengthened by the specialty’s expanding service scope beyond traditional OB/GYN. More than one-third of women’s health visits historically centered on reproductive care and contraception, but the most valuable women’s health platforms now integrate fertility services, mammography, in-office laboratory, menopause management programs, urogynecology, behavioral health, and aesthetic or wellness offerings, creating multiple revenue layers per patient encounter and dramatically higher per-patient lifetime value.[5] Despite more than a decade of platform formation activity, the vast majority of the estimated 40,000+ OB/GYN and women’s health providers in the U.S. remain unaffiliated with a management service organization, representing substantial remaining consolidation runway for both new and established platforms.[6]
Women’s health practice valuations are driven by a combination of scale, service line breadth, provider mix, delivery volume, geographic positioning, ancillary service revenue, and malpractice profile. Practices that have expanded beyond traditional OB/GYN into higher-margin ancillary and multi-specialty services, such as ultrasound, lab, mammography, fertility, urogynecology, and aesthetics, typically command higher valuation multiples because they offer buyers stronger growth potential and less reliance on a single service line. Ancillary service integration is one of the clearest drivers of valuation premiums, while malpractice exposure, particularly in obstetrics, remains one of the most important discount factors, with buyers closely evaluating claims history, tail coverage, insurance costs, and delivery volume when underwriting transactions.[7]
PGP believes that practices with these attributes and greater than $3 million of EBITDA are increasingly seeing valuation multiples approaching double digits in this market. Groups with some, but not all, of the characteristics of a scalable platform and less than $3 million of EBITDA are generally trading at mid- to high-single-digit EBITDA multiples, while smaller practices with less than $1 million of EBITDA are typically valued at low- to mid-single-digit EBITDA multiples.
Benchmark transactions include the Partners Group acquisition of Axia Women’s Health from Audax Private Equity, a second-recapitalization transaction representing a national platform of 500+ providers across 150 locations in five states, and the Altas Partners and KKR-backed recapitalization of Unified Women’s Healthcare, now the largest U.S. women’s health MSO with approximately 2,300 providers including integrated maternal-fetal medicine. These platform-level transactions validate that scaled, multi-specialty women’s health organizations trade at premium valuations comparable to the highest-multiple physician practice categories.[6][7]
Since 2022, PGP has completed more than seven women’s health transactions, positioning the firm as one of the most active advisors in the sector. Based on its transaction experience and active market mandates, PGP has identified five distinct categories of well-capitalized acquirers actively deploying capital:
| Date | Buyer | Target | Commentary |
|---|---|---|---|
| Apr 2024 | Femwell | The Woman’s Group (Tampa, FL) | The transaction further expanded Femwell’s presence within the state of Florida as The Woman’s Group had more than 30 providers across four locations. (Advised by PGP) |
| Aug 2024 | Together Women’s Health (Shore Capital) | true. Women’s Health (Grand Rapids, MI — concierge menopause) | Virtual and in-person midlife/menopause/sexual health model. |
| Dec 2024 | Webster Equity Partners | WomanCare (Arlington Heights, IL platform formation) | The transaction included one of the founding practices, WomanCare, to form the newest women’s health platform, Nova Women’s Health. WomanCare comprised of more than 20 providers and four locations at the time of the sale. (Advised by PGP) |
| Dec 2024 | Webster Equity Partners | Women’s HealthFirst (Palatine, IL platform formation) | The transaction included one of the founding practices, Women’s HealthFirst, to form the newest women’s health platform, Nova Women’s Health. Women’s HealthFirst comprised of just shy of ~20 providers and five locations at the time of the sale. (Advised by PGP) |
| Jan 2025 | IVI RMA (KKR) | Reproductive Health & Wellness, Rise Fertility, and Halo Fertility (CA) | IVI RMA expands Southern California presence through simultaneous acquisition of three fertility platforms. |
| Jan 2025 | Nova Women’s Health Partners (Webster Equity Partners) | MidTown OBGYN (Atlanta, GA) | Nova Women’s Health Partners adds first Georgia practice; continued national build-out. |
| Mar 2025 | Pinnacle Fertility (Webster Equity Partners) | IVF Michigan & Ohio Fertility Centers (MI / OH) | Pinnacle Fertility expands Midwest footprint across Michigan and Ohio. |
| Mar 2025 | HRC Fertility | Zouves Fertility Center (San Francisco Bay Area, CA) | HRC Fertility enters Bay Area market. |
| Jun 2025 | Together Women’s Health (Shore Capital) | The Perinatal Group (first MFM partnership) | TWH’s entry into maternal-fetal medicine. |
| Jun 2025 | Together Women’s Health (Shore Capital) | MidSouth OBGYN (Memphis, TN) | TWH’s first Tennessee entry; network now 20+ practices, 175+ providers. |
| Sep 2025 | Together Women’s Health (Shore Capital) | Women’s Health Mississippi (5 practice affiliations) | Expansion into Mississippi market, TWH’s presence extends to 8 states. |
| Nov 2025 | Together Women’s Health (Shore Capital) | WOMEN Obstetrics & Gynecology (Tennessee) | Continued Tennessee densification. |
| Nov 2025 | Pinnacle Fertility (Webster Equity Partners) | Tulsa Fertility Center (Tulsa, OK) | Pinnacle Fertility expands national network into Oklahoma. |
| Nov 2025 | IVI RMA (KKR) | Mid-Iowa Fertility (IA) | IVI RMA enters Iowa market; continued Midwest geographic expansion. |
| Nov 2025 | L Catterton + Amulet Capital Partners | US Fertility (platform recapitalization) | Strategic partnership recapitalizes national fertility platform; accelerates growth and expands access to reproductive care. |
| Dec 2025 | IVI RMA (KKR) | Island Reproductive Services (New York City, NY) | IVI RMA enters New York City market. |
| Jan 2026 | Northwell Health | Garden OB/GYN (Garden City, NY) | Garden OB/GYN was one of the largest independent women’s health Practice’s in the New York market before being acquired by Northwell Health. (Advised by PGP) |
| Feb 2026 | INVO Fertility (NASDAQ: IVF) | Family Beginnings (Indianapolis, IN) | INVO Fertility expands into Indiana market. |
| Mar 2026 | CSG.BIO | Hanabusa IVF + Asian Egg Bank (CA) | CSG.BIO builds global fertility and egg preservation platform through dual acquisition. |
| Apr 2026 | Olympus Cosmetic Group (VSS Capital Partners) | Acadia Women’s Health (Baton Rouge, LA) | Acadia Women’s Health was a combination of a cosmetic surgery provider to women in addition to offering OB/GYN services at the time they partnered with Olympus. (Advised by PGP) |
| May 2026 | Pinnacle Fertility (Webster Equity Partners) | Genesis Fertility (New York, NY) | Pinnacle Fertility expands New York presence. |
| Jun 2026 | Pinnacle Fertility (Webster Equity Partners) | Adore Fertility (SC) | Pinnacle Fertility enters South Carolina; continued Southeast expansion. |
Client Advised by PGP
PGP has developed meaningful domain expertise representing women’s health practice founders across platform formations, recapitalizations, and add-on transactions. Our advisory work in women’s health includes, among others:
Several sector-specific factors are making this an especially attractive time for independent women’s health practice owners to consider a transaction:
The Corporate Practice of Medicine, which generally limits non-physician ownership of medical practices, has shaped how women’s health MSOs are structured. Leading platforms preserve physician ownership and control of clinical care while shifting non-clinical operations to the management organization.
Under this structure, physicians should continue to make all clinical decisions, including patient care, provider scheduling, call coverage, and service offerings. The MSO supports the practice with administrative functions such as revenue cycle management, HR, marketing, IT, group purchasing, payor contracting support, and operational leadership.
For women’s health practices, maintaining long-term patient-provider relationships is especially important. Practice owners evaluating a transaction should carefully assess whether a potential MSO partner protects clinical autonomy, continuity of care, provider scheduling flexibility, and the practice’s ability to maintain its full scope of services.
Women’s health has moved decisively from an emerging consolidation story to a mature and well-validated institutional asset class. The second recapitalizations of Unified Women’s Healthcare and Axia Women’s Health have settled the question of whether PE investment in OB/GYN and women’s health generates returns for physician partners and that proof of concept has brought a new generation of sponsors, platform operators, and strategic acquirers into the category. The women’s health M&A market in 2026 is broader, better capitalized, and more competitive than it has been at any point since Unified was formed in 2013.
The dynamics now favoring sellers are not simply cyclical. The national maternity care access crisis is structural and rooted in workforce shortages, facility closures, and geographic inequity that will persist for decades. Buyers willing to deploy capital into underserved and rural markets actively seeking physician partners. Well-positioned independent practices have pricing leverage that reflects their scarcity value. Simultaneously, the expanding scope of women’s health beyond traditional OB/GYN is creating a category of comprehensive women’s health platforms that trade at meaningfully higher valuations than single-specialty practices. Groups that have already built this breadth, or that have the infrastructure to support it, are uniquely positioned in the current transaction environment.
For independent women’s health practice owners, a transaction with the right partner is not an exit from the practice you built. It is an opportunity to create a stronger, better-supported version of it, with less administrative burden, improved operations, access to capital for growth, and the potential to build meaningful equity value over time. Choosing the right partner is one of the most important decisions a physician founder will make. Outcomes can vary significantly depending on which buyers are approached, how the process is managed, and how the practice is positioned. PGP’s role is to position your practice effectively, ensure the transaction reflects the full value of what you have built, and help you select a partner that is the right cultural fit, preserves physician control, and provides the resources needed to continue delivering high-quality care.
No obligation. Completely confidential. Typically 30 minutes.
Sources & Citations
Physician Growth Partners · This content is provided for informational purposes only and does not constitute legal, financial, or investment advice. All transaction data sourced as cited. © 2026 Physician Growth Advisors, LLC. All rights reserved.